Both in Biotechnology

Kalaris Therapeutics vs Champions Oncology

Over the past year KLRS returned −54.3% and CSBR returned −24.9%; their daily moves had a correlation of 0.10.

KLRS −54.3% CSBR −24.9%Growth of $1, one year, split-adjusted
MetricKLRSCSBR
Price$2.90$4.79
Market cap$69.0M$66.7M
Today+1.93%−2.84%
1 month−28.0%−2.8%
6 months−45.3%−18.0%
Year to date−65.6%−30.7%
1 year−48.3%—
Revenue growth (YoY)—+8.8%
Gross margin—50.5%
Net margin—−2.8%
P/E (TTM)——
Price / sales—1.1×
Net cash$93.5M$4.4M
Dividend yield——
Volatility (60d)58.9%44.8%
Short % of float5.7%1.4%
Next earnings——

Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).

KLRS vs CSBR: Kalaris Therapeutics vs Champions Oncology Stock Comparison | Gainbot